212 related articles for article (PubMed ID: 25636420)
1. Early survival prediction after intra-arterial therapies: a 3D quantitative MRI assessment of tumour response after TACE or radioembolization of colorectal cancer metastases to the liver.
Chapiro J; Duran R; Lin M; Schernthaner R; Lesage D; Wang Z; Savic LJ; Geschwind JF
Eur Radiol; 2015 Jul; 25(7):1993-2003. PubMed ID: 25636420
[TBL] [Abstract][Full Text] [Related]
2. Transarterial chemoembolization in soft-tissue sarcoma metastases to the liver - the use of imaging biomarkers as predictors of patient survival.
Chapiro J; Duran R; Lin M; Mungo B; Schlachter T; Schernthaner R; Gorodetski B; Wang Z; Geschwind JF
Eur J Radiol; 2015 Mar; 84(3):424-430. PubMed ID: 25542065
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Existing Response Criteria in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Using a 3D Quantitative Approach.
Tacher V; Lin M; Duran R; Yarmohammadi H; Lee H; Chapiro J; Chao M; Wang Z; Frangakis C; Sohn JH; Maltenfort MG; Pawlik T; Geschwind JF
Radiology; 2016 Jan; 278(1):275-84. PubMed ID: 26131913
[TBL] [Abstract][Full Text] [Related]
4. Imaging Biomarkers of Tumor Response in Neuroendocrine Liver Metastases Treated with Transarterial Chemoembolization: Can Enhancing Tumor Burden of the Whole Liver Help Predict Patient Survival?
Sahu S; Schernthaner R; Ardon R; Chapiro J; Zhao Y; Sohn JH; Fleckenstein F; Lin M; Geschwind JF; Duran R
Radiology; 2017 Jun; 283(3):883-894. PubMed ID: 27831830
[TBL] [Abstract][Full Text] [Related]
5. Which Criteria Applied in Multi-Phasic CT Can Predict Early Tumor Response in Patients with Hepatocellular Carcinoma Treated Using Conventional TACE: RECIST, mRECIST, EASL or qEASL?
Zhao Y; Duran R; Bai W; Sahu S; Wang W; Kabus S; Lin M; Han G; Geschwind JF
Cardiovasc Intervent Radiol; 2018 Mar; 41(3):433-442. PubMed ID: 29086058
[TBL] [Abstract][Full Text] [Related]
6. Modified response evaluation criteria in solid tumors and European Association for The Study of the Liver criteria using delayed-phase imaging at an early time point predict survival in patients with unresectable intrahepatic cholangiocarcinoma following yttrium-90 radioembolization.
Camacho JC; Kokabi N; Xing M; Prajapati HJ; El-Rayes B; Kim HS
J Vasc Interv Radiol; 2014 Feb; 25(2):256-65. PubMed ID: 24461131
[TBL] [Abstract][Full Text] [Related]
7. 3D Quantitative tumour burden analysis in patients with hepatocellular carcinoma before TACE: comparing single-lesion vs. multi-lesion imaging biomarkers as predictors of patient survival.
Fleckenstein FN; Schernthaner RE; Duran R; Sohn JH; Sahu S; Zhao Y; Hamm B; Gebauer B; Lin M; Geschwind JF; Chapiro J
Eur Radiol; 2016 Sep; 26(9):3243-52. PubMed ID: 26762942
[TBL] [Abstract][Full Text] [Related]
8. Reliable prediction of survival in advanced-stage hepatocellular carcinoma treated with sorafenib: comparing 1D and 3D quantitative tumor response criteria on MRI.
Doemel LA; Chapiro J; Laage Gaupp F; Savic LJ; Kucukkaya AS; Petukhova A; Tefera J; Zeevi T; Lin M; Schlachter T; Jaffe A; Strazzabosco M; Patel T; Stein SM
Eur Radiol; 2021 May; 31(5):2737-2746. PubMed ID: 33123796
[TBL] [Abstract][Full Text] [Related]
9. Lipiodol as an intra-procedural imaging biomarker for liver tumor response to transarterial chemoembolization: Post-hoc analysis of a prospective clinical trial.
Letzen BS; Malpani R; Miszczuk M; de Ruiter QMB; Petty CW; Rexha I; Nezami N; Laage-Gaupp F; Lin M; Schlachter TR; Chapiro J
Clin Imaging; 2021 Oct; 78():194-200. PubMed ID: 34022765
[TBL] [Abstract][Full Text] [Related]
10. Quantitative volumetric functional MR imaging: an imaging biomarker of early treatment response in hypo-vascular liver metastasis patients after yttrium-90 transarterial radioembolization.
Zhu X; Sobhani F; Xu C; Pan L; Ghasebeh MA; Kamel IR
Abdom Radiol (NY); 2016 Aug; 41(8):1495-504. PubMed ID: 26960726
[TBL] [Abstract][Full Text] [Related]
11. Identifying Staging Markers for Hepatocellular Carcinoma before Transarterial Chemoembolization: Comparison of Three-dimensional Quantitative versus Non-three-dimensional Imaging Markers.
Chapiro J; Duran R; Lin M; Schernthaner RE; Wang Z; Gorodetski B; Geschwind JF
Radiology; 2015 May; 275(2):438-47. PubMed ID: 25531387
[TBL] [Abstract][Full Text] [Related]
12. Volumetric Enhancing Tumor Burden at CT to Predict Survival Outcomes in Patients with Neuroendocrine Liver Metastases after Intra-arterial Treatment.
Assouline J; Cannella R; Porrello G; de Mestier L; Dioguardi Burgio M; Raynaud L; Hentic O; Cros J; Tselikas L; Ruszniewski P; Vullierme MP; Vilgrain V; Duran R; Ronot M
Radiol Imaging Cancer; 2023 Jan; 5(1):e220051. PubMed ID: 36607243
[TBL] [Abstract][Full Text] [Related]
13. Identifying enhancement-based staging markers on baseline MRI in patients with colorectal cancer liver metastases undergoing intra-arterial tumor therapy.
Ghani MA; Fereydooni A; Chen E; Letzen B; Laage-Gaupp F; Nezami N; Deng Y; Gan G; Thakur V; Lin M; Papademetris X; Schernthaner RE; Huber S; Chapiro J; Hong K; Georgiades C
Eur Radiol; 2021 Dec; 31(12):8858-8867. PubMed ID: 34061209
[TBL] [Abstract][Full Text] [Related]
14. mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE).
Prajapati HJ; Spivey JR; Hanish SI; El-Rayes BF; Kauh JS; Chen Z; Kim HS
Ann Oncol; 2013 Apr; 24(4):965-73. PubMed ID: 23223331
[TBL] [Abstract][Full Text] [Related]
15. Transarterial Radioembolization Following Chemoembolization for Unresectable Hepatocellular Carcinoma: Response Based on Apparent Diffusion Coefficient Change is an Independent Predictor for Survival.
Klompenhouwer EG; Dresen RC; Verslype C; Laenen A; Bonne L; Vandecaveye V; Maleux G
Cardiovasc Intervent Radiol; 2018 Nov; 41(11):1716-1726. PubMed ID: 29872894
[TBL] [Abstract][Full Text] [Related]
16. Unresectable hepatocellular carcinoma: MR imaging after intraarterial therapy. Part II. Response stratification using volumetric functional criteria after intraarterial therapy.
Bonekamp S; Halappa VG; Geschwind JF; Li Z; Corona-Villalobos CP; Reyes D; Bhagat N; Cosgrove DP; Pawlik TM; Mezey E; Eng J; Kamel IR
Radiology; 2013 Aug; 268(2):431-9. PubMed ID: 23616632
[TBL] [Abstract][Full Text] [Related]
17. EASL- and mRECIST-evaluated responses to combination therapy of sorafenib with transarterial chemoembolization predict survival in patients with hepatocellular carcinoma.
Liu L; Wang W; Chen H; Zhao Y; Bai W; Yin Z; He C; Jia J; Yang M; Xia J; Fan D; Han G
Clin Cancer Res; 2014 Mar; 20(6):1623-31. PubMed ID: 24493832
[TBL] [Abstract][Full Text] [Related]
18. Renal Cell Carcinoma Metastatic to the Liver: Early Response Assessment after Intraarterial Therapy Using 3D Quantitative Tumor Enhancement Analysis.
Fleckenstein FN; Schernthaner RE; Duran R; Sohn JH; Sahu S; Marshall K; Lin M; Gebauer B; Chapiro J; Salem R; Geschwind JF
Transl Oncol; 2016 Oct; 9(5):377-383. PubMed ID: 27641641
[TBL] [Abstract][Full Text] [Related]
19. Transarterial (chemo)embolisation versus no intervention or placebo for liver metastases.
Swierz MJ; Storman D; Riemsma RP; Wolff R; Mitus JW; Pedziwiatr M; Kleijnen J; Bala MM
Cochrane Database Syst Rev; 2020 Mar; 3(3):CD009498. PubMed ID: 32163181
[TBL] [Abstract][Full Text] [Related]
20. Comparison of tumor response assessment methods in patients with metastatic colorectal cancer after locoregional therapy.
Akinwande O; Philips P; Scoggins CR; Kelly L; Tatum C; Hahl M; McMasters KM; Martin RC
J Surg Oncol; 2016 Mar; 113(4):443-8. PubMed ID: 27060707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
